Amgen Inc. $AMGN Shares Purchased by Plato Investment Management Ltd

Plato Investment Management Ltd raised its position in Amgen Inc. (NASDAQ:AMGN) by 12.5% during the third quarter, Holdings Channel.com reports. The firm owned 20,304 shares of the medical research company’s stock after buying an additional 2,258 shares during the period. Plato Investment Management Ltd’s holdings in Amgen were worth $5,686,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Laurel Wealth Advisors LLC boosted its holdings in shares of Amgen by 27,765.8% during the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after purchasing an additional 6,676,575 shares during the last quarter. Norges Bank acquired a new stake in Amgen in the 2nd quarter worth about $1,663,726,000. Vanguard Group Inc. grew its holdings in Amgen by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after buying an additional 841,117 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Amgen by 5.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after acquiring an additional 687,735 shares during the last quarter. Finally, Mizuho Markets Cayman LP purchased a new position in shares of Amgen during the 2nd quarter worth about $135,597,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Up 4.5%

Shares of NASDAQ AMGN opened at $384.20 on Friday. The stock has a fifty day moving average price of $334.45 and a 200 day moving average price of $311.49. The company has a current ratio of 1.14, a quick ratio of 0.99 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $385.12. The company has a market cap of $206.88 billion, a P/E ratio of 27.00, a P/E/G ratio of 3.90 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the business earned $5.31 earnings per share. The company’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Friday, February 13th. Amgen’s payout ratio is 66.90%.

Insider Activity

In other news, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 10,908 shares of company stock worth $3,674,966 over the last 90 days. Company insiders own 0.76% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on AMGN. TD Cowen restated a “buy” rating on shares of Amgen in a report on Wednesday. Scotiabank began coverage on shares of Amgen in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price objective for the company. Oppenheimer set a $400.00 price objective on Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Finally, Daiwa Securities Group upped their price target on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $351.65.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.